Testing fungal biomarkers for directing antifungal therapy for invasive fungal disease in patients with high-risk haematological malignancies in a University Teaching Hospital: a cost benefit analysis

被引：0
|
作者：
Perera, N. [1 ]
Lim, F. H. [1 ]
Saibudeen, A. [1 ]
Hodgson, K. [1 ]
机构：
[1] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
来源：
MYCOSES | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P126
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [41] THE BENEFIT OF OBTAINING 24-HOUR URINE TESTING BEFORE PRESCRIBING PREVENTIVE PHARMACOLOGICAL THERAPY TO PATIENTS WITH HIGH-RISK URINARY STONE DISEASE
    Hsi, Ryan
    Yan, Phyllis
    Crivelli, Joseph
    Shahinian, Vahakn
    Hollingsworth, John
    JOURNAL OF UROLOGY, 2021, 206 : E219 - E219
  • [42] Difficulties in using 1,3-β-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies - high frequency of false-positive results and their analysis
    Racil, Zdenek
    Kocmanova, Iva
    Lengerova, Martina
    Weinbergerova, Barbara
    Buresova, Lucie
    Toskova, Martina
    Winterova, Jana
    Timilsina, Shira
    Rodriguez, Isa
    Mayer, Jiri
    JOURNAL OF MEDICAL MICROBIOLOGY, 2010, 59 (09) : 1016 - 1022
  • [43] COST-EFFECTIVENESS OF ANTIGUNGAL PROPHYLAXIS WITH POSACONAZOLE VERSUS STANDARD AZOLE THERAPY IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG HIGH RISK HAEMATOLOGY PATIENTS IN CZECH REPUBLIC
    Suchankova, E.
    Dolezal, T.
    Simonova, J.
    VALUE IN HEALTH, 2009, 12 (07) : A380 - A380
  • [44] Posaconazole vs standard azole (FLU/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high-risk neutropenic patients: Results of a randomized, multicenter trial.
    Cornely, O
    Maertens, J
    Winston, D
    Perfect, J
    Helfgott, D
    Ullmann, A
    Holowiecki, J
    Stockelberg, D
    Goh, YT
    Petrini, M
    Walsh, T
    Gogate, J
    Hardalo, C
    Angulo-Gonzalez, D
    BLOOD, 2005, 106 (11) : 524A - 524A
  • [45] COST ANALYSIS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN BRAZIL
    Xue, M.
    Gao, X.
    Ferreira, C. N.
    Stephens, J. M.
    Haider, S.
    Figueiredo Valente, M. L.
    Charbonneau, C.
    VALUE IN HEALTH, 2015, 18 (07) : A820 - A820
  • [46] The efficacy of IV amphotericin B antifungal prophylaxis in preventing invasive fungal disease (IFD) - a retrospective analysis of patients treated for acute lymphoblastic leukaemia at the Paediatric Haematology and Oncology Department, Addenbrooke's Hospital
    Green, S.
    Seymour, C.
    Gattens, M.
    Messahel, B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 66 - 67
  • [47] COST ANALYSIS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B AND CASPOFUNGIN FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN LEBANON
    Helou, G.
    Gao, C.
    Xue, M.
    Tarcha, N.
    Charbonneau, C.
    VALUE IN HEALTH, 2016, 19 (07) : A583 - A584
  • [48] Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany
    Heimann, S. M.
    Vehreschild, M. J. G. T.
    Meintker, L.
    Heinz, W.
    Schroeder, T.
    von Bergwelt-Baildon, M.
    Cornely, O. A.
    Vehreschild, J. J.
    TRANSPLANT INFECTIOUS DISEASE, 2014, 16 (06) : 968 - 974
  • [49] Can bacteraemia lead to false positive results in 1,3-beta-D-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections
    Metan, Gokhan
    Koc, Ayse Nedret
    Agkus, Cigdem
    Kaynar, Leyla Gul
    Alp, Emine
    Eser, Bulent
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2012, 29 (03): : 169 - 171
  • [50] COST ANALYSIS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN BAND CASPOFUNGIN FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN SAUDI ARABIA
    Thaqafi, A. A.
    Xue, M.
    Farahat, F.
    Gao, X.
    Wafy, M. H.
    Fahti, M.
    Ibrahim, A.
    Charbonneau, C.
    VALUE IN HEALTH, 2015, 18 (07) : A667 - A667
12345